UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,620	01/13/2006	Pninna Fishman	FISHMAN18A	1534
1444 DDOWDV AN	444 7590 01/25/2008 BROWDY AND NEIMARK, P.L.L.C.		EXAMINER	
624 NINTH ST			HENRY, M	ICHAEL C
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER NUMBER
***************************************	1, 20 20001 3303	•	1623	
			MAIL DATE	DELIVERY MODE
			01/25/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/564,620	FISHMAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michael C. Henry	1623				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on	_•					
2a) This action is <b>FINAL</b> . 2b) ∑ This						
3) Since this application is in condition for allowar	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-10 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-6,9 and 10</u> is/are rejected.						
7) Claim(s) 7 and 8 is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
<ul><li>2. Certified copies of the priority documents have been received in Application No</li><li>3. Copies of the certified copies of the priority documents have been received in this National Stage</li></ul>						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
decline attached detailed entire detail for a first of the detailed deploy for redelived.						
Attachment(s)	A) 🗖 (-t	(DTO 412)				
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application						
Paper No(s)/Mail Date <u>01/13/06 &amp; 04/20/07</u> . 6) Other:						

10/564,620 Art Unit: 1623

### **DETAILED ACTION**

Claims 1-10 are pending in application

## Information Disclosure Statement

The information disclosure statement filed complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. It has been placed in the application file and the information referred to therein has been considered as to the merits.

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-6, 9-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fishman (WO2004/045627 A1).

In claim 1, applicant claims a method for the treatment of accelerated bone resorption in a mammal subject, the method comprises administering to said subject in need of said treatment an amount of an A3 adenosine receptor agonist (A3AR agonist), the amount being effective to inhibit bone resorption.

Fishman discloses a method of treating inflammatory arthritis comprising administering to a subject an A3 adenosine receptor agonist (A3AR agonist) (see abstract and claims).

Furthermore, Fishman discloses uses the A3 receptor agonists IB-MECA and CI-IB-MECA for the said treatment (see abstract and claims). Also, Fishman reduces the bone loss (bone

Application/Control Number:

10/564,620

Art Unit: 1623

resorption) in a subject by administering to the subject IB-MECA. In addition, Fishman measures the loss of bone and reports that bone loss was markedly lower in the subjects treated with IB-MECA(see histology score in example 1C). Claims 2-6 are drawn said method, wherein the subject is human, the treatment of bone resorption is induced by specific conditions, the administration is oral, the A3AR agonist is administered specific times per day and the use of specific A3AR agonist including IB-MECA and CI-IB-MECA.

The difference between applicant's claimed method and the method of Fishman is that Fishman's do not disclose that the bone resorption that is treated is accelerated.

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made, in view of Fishman, to treat bone resorption (bone loss) in a subject regardless of the type of bone loss by administering to the said subject the A3AR agonist such as IB-MECA or CL-IB-MECA, since Fishman discloses that A3AR agonist such as IB-MECA or CL-IB-MECA can be used to treat bone resorption (bone loss).

One having ordinary skill in the art would have been motivated in view of Fishman, to treat bone resorption (bone loss) in a subject, regardless of the type of bone loss, by administering to the said subject an A3AR agonist such as IB-MECA or CL-IB-MECA, because a skilled artisan would reasonably be expected to use or administer A3AR agonist such as IB-MECA or CL-IB-MECA, to treat bone resorption (the same condition or disease) based on factors such as type and/or severity of the condition or disorder. It should be noted that the use of different schedules of administration or dosages are common in the art and is well within the

10/564,620

Art Unit: 1623

purview of a skilled artisan and depends on factors such as the severity or type of the rheumatoid arthrithis and the weight, age and type of the subject treated.

# Allowable Subject Matter

Claims 7 and 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The method recited in claims 7 and 8 treats accelerated bone resorption with compounds that possess structural differences to the compounds of the prior art and these differences are not suggested in the prior art, nor are obvious over the prior art. For example, the compounds of the claims 7 and 8 contain chemical moieties or substituents on N6 of the purine ring that are different, not suggested in the prior art, nor are obvious over the prior art.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Application/Control Number:

10/564,620 Art Unit: 1623 Page 5

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry

Shaojia Anna Jiang, Ph.D. Supervisory Patent Examiner

Art Unit 1623

January 21, 2008.